Search Results - "LICHTIN, A. E"

Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology by GEORGE, J. N, WOOLF, S. H, LICHTIN, A. E, MCMILLAN, R, OKERBLOOM, J. A, REGAN, D. H, WARRIER, I, RASKOB, G. E, WASSER, J. S, ALEDORT, L. M, BALLEM, P. J, BLANCHETTE, V. S, BUSSEL, J. B, CINES, D. B, KELTON, J. G

Get full text

Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials by Seidenfeld, Jerome, Piper, Margaret, Flamm, Carole, Hasselblad, Victor, Armitage, James O., Bennett, Charles L., Gordon, Michael S., Lichtin, Allan E., Wade, James L., Woolf, Steven, Aronson, Naomi

“…Epoetin treatment offers an attractive but costly alternative to red blood cell transfusion for managing anemia associated with cancer therapy. The goal of…”
Get full text

Platelet larceny: spurious hypoxaemia due to extreme thrombocytosis by Mehta, A, Lichtin, A. E, Vigg, A, Parambil, J. G

“…Rapid oxygen consumption by markedly increased numbers of hypermetabolic leukocytes in leukaemic patients resulting in the apparent diagnosis of hypoxaemia on…”
Get full text

G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment by Bolwell, B J, Fishleder, A, Andresen, S W, Lichtin, A E, Koo, A, Yanssens, T, Burwell, R, Baucco, P, Green, R

“…G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet…”
Get more information

What evaluation should be done for an apparently healthy patient with an increased mean corpuscular volume (MCV)? by Lichtin, A E

Get full text

Hypocupremia and bone marrow failure by Haddad, A.S, Subbiah, V, Lichtin, A.E, Theil, K.S, Maciejewski, J.P

“…1 Experimental Hematology and Hematopoiesis Section 2 Department of Hematologic Oncology and Blood Disorders; Taussig Cancer Center 3 Department of Clinical…”
Get full text

An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology by Silver, Richard T., Woolf, Steven H., Hehlmann, Rüdiger, Appelbaum, Frederick R., Anderson, James, Bennett, Charles, Goldman, John M., Guilhot, Francois, Kantarjian, Hagop M., Lichtin, Alan E., Talpaz, Moshe, Tura, Sante

“…Because there are differing opinions regarding treatment of patients in the chronic phase of chronic myeloid leukemia (CML), the American Society of Hematology…”
Get full text

Incidence of mixed chimerism using busulfan/cyclophosphamide containing regimens in allogeneic bone marrow transplantation by Fishleder, A J, Bolwell, B, Lichtin, A E

“…The incidence of mixed chimerism (MC) following allogeneic bone marrow transplantation (allo-BMT) is in part a measure of the marrow ablative effect of…”
Get more information

High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer by Kalaycioglu, M E, Lichtin, A E, Andresen, S W, Tuason, L, Bolwell, B J

“…High doses of combination alkylating agents have shown promise in the treatment of breast cancer but are complicated by significant toxicity. Busulfan and…”
Get more information

Hematologic complications of rheumatic disease therapies by George, C S, Lichtin, A E

“…Hematologic side effects of rheumatic disease therapies are generally mild and reversible; however, the clinician must be alert for potential profound and…”
Get more information

Acute leukemia with a very high leukocyte count: confronting a medical emergency by Majhail, Navneet S, Lichtin, Alan E

“…From 5% to 30% of adult patients with acute leukemias present with hyperleukocytosis--very high white blood cell counts (> 100,000 cells/mm3)--and symptoms of…”
Get full text

Precursor Langerhans cell histiocytosis. An unusual histiocytic proliferation in a patient with persistent non-Hodgkin lymphoma and terminal acute monocytic leukemia by Segal, G H, Mesa, M V, Fishleder, A J, Stoler, M H, Weick, J K, Lichtin, A E, Tubbs, R R

“…Langerhans cell precursors are considered to be identical to their mature counterparts except for the lack of Birbeck granules. Proliferations composed of such…”
Get more information

Pseudo-gamma heavy chain (IgG4 lambda) deposition disease by Tubbs, R R, Berkley, V, Valenzuela, R, McMahon, J T, Gephardt, G N, Fishleder, A J, Nally, J V, Pohl, M A, Bukowski, R M, Lichtin, A E

“…Two patients with Ig deposition disease presented with acute renal failure, moderate proteinuria, and hematuria. A plasmacytoid lymphocytic infiltrate was…”
Get more information

Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality by Majhail, Navneet S, Lichtin, Alan E

“…Although the antiplatelet agent clopidogrel is associated with an increased incidence of thrombotic thrombocytopenic purpura (TTP), available evidence is not…”
Get full text

What is the best way to determine if thrombocytopenia in a patient on multiple medications is drug-induced? by Majhail, Navneet S, Lichtin, Alan E

Get full text

Antithrombotic, anticoagulant, and thrombolytic agents by Terezhalmy, G T, Lichtin, A E

“…There are a growing number of clinical indications for the use of antithrombotic, anticoagulant, and thrombolytic agents. Clinicians must recognize that these…”
Get more information

2', 5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells by MARAN, A, WALLER, C. F, TORRENCE, P. F, SILVERMAN, R. H, PARANJAPE, J. M, GUIYING LI, WEI XIAO, ZHANG, K, KALAYCIO, M. E, MAITRA, R. K, LICHTIN, A. E, BRUGGER, W

“…We report an RNA targeting strategy, which selectively degrades bcr/abl mRNA in chronic myelogenous leukemia (CML) cells. A 2', 5'-tetraadenylate activator…”
Get full text

Efficacy of intensive plasmapheresis in thrombotic thrombocytopenic purpura by Lichtin, A E, Schreiber, A D, Hurwitz, S, Willoughby, T L, Silberstein, L E

“…Forty-one patients with thrombotic thrombocytopenic purpura were treated at the Hospital of the University of Pennsylvania, Philadelphia, between 1975 and…”
Get more information

Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia by Mohan, Sanjay R, Clemente, Michael J, Afable, Manuel, Cazzolli, Heather N, Bejanyan, Nelli, Wlodarski, Marcin W, Lichtin, Alan E, Maciejewski, Jaroslaw P

“…1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA 2 Division of Pediatric…”
Get full text

How safe are erythropoiesis-stimulating agents? by Lichtin, Alan E

Get full text